---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040049"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:59:45.211150+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q3 revenue $2.5M, net loss $6.0M; receives $9.0M Gates Foundation grant

## Summary
- Revenue $2.5M, down from $5.1M in prior year due to declining COVID-19 test demand.
- Net loss of $6.0M ($0.20/sh) vs $1.4M loss ($0.04/sh) in prior year.
- Received $9.0M grant from Bill & Melinda Gates Foundation for TB test development on Co-Dx PCR platform.
- Expects EUA submission to FDA for Co-Dx PCR Pro platform and COVID-19 assay by year-end 2023.
- Cash and securities $63.4M as of Sept 30, 2023; repurchased 149,041 shares at $1.12 avg.

## SEC filing metadata
- accession: 0001493152-23-040049
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/0001493152-23-040049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040049
- JSON: https://secwatch.observer/filing/0001493152-23-040049.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040049.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported quarter ended September 30, 2023 results: revenue $2.5 million, net income $6.0 million, EPS $0.20 per fully diluted share.
  - Period: quarter ended September 30, 2023
  - Revenue: $2.5 million
  - Net income: $6.0 million
  - EPS: $0.20 per fully diluted share
  - Result: reported results
  source text: the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Results: ● Revenue of $2.5 million, down from $5.1 million during the prior year primarily due to the anticipated decline in global demand for COVID-19 tests. Grant revenue totaled $2.3 million while product
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315223040049/0001493152-23-040049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.